To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes.

To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes. 1. Requirement for manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers (a) In general Section 1128G(a) of the Social Security Act (42 U.S.C. 1320a–7h(a)) is amended by adding at the end the following new paragraph: (3) Certain product samples (A) In general In addition to the requirements under paragraphs (1)(A) and (2), on the 90th day of each calendar year (beginning with 2023), any applicable manufacturer that provides a payment or other transfer of value that is a product sample described in subparagraph (B) to any covered recipient (or to an entity or individual at the request of, or designated on behalf of, such a covered recipient) shall submit to the Secretary, in such electronic form as the Secretary shall require, the following information with respect to the preceding calendar year: (i) The total quantity of all such payments or other transfers of value provided to covered recipients. (ii) The total value of all such payments or other transfers of value provided to covered recipients. (iii) If applicable, information described in clauses (vii) and (viii) of paragraph (1)(A) with respect to such a payment or other transfer of value. (B) Product sample described For purposes of subparagraph (A), a product sample described in this subparagraph is a product sample that is not intended to be sold and is intended for patient use. . (b) Public availability of information Section 1128G(c)(1)(C) of the Social Security Act (42 U.S.C. 1320a–7h(c)(1)(C)) is amended— (1) in clause (ii)— (A) by striking (ii) (ii) (I) (B) by striking , as applicable; , as applicable; and (C) by adding at the end the following new subclause: (II) with respect to information submitted under paragraph (3) of subsection (a), contains information that is presented by the name of the applicable manufacturer, the total amount of all payments or other transfers of value described in such paragraph provided to covered recipients, the total value of all such payments or other transfers of value provided to covered recipients, and the name of the covered drug, device, biological, or medical supply, as applicable; ; (2) in clause (viii), by striking , and (3) in clause (ix), by striking the period at the end and inserting ; and (4) by adding at the end the following new clause: (x) in the case of information submitted under paragraph (3) of subsection (a), lists such information separately from the other information submitted under subsection (a) and presents such information by the name of the applicable manufacturer, the total quantity of all payments or other transfers of value described in such paragraph provided to covered recipients, the total value of all such payments or other transfers of value provided to covered recipients, and the name of the covered drug, device, biological, or medical supply, as applicable. . (c) Conforming amendment Section 1128G(e)(10)(B)(ii) of the Social Security Act (42 U.S.C. 1320a–7h(e)(10)(B)(ii)) is amended by striking Product samples Except for purposes of paragraph (3) of subsection (a), product samples

Summary: This bill requires drug manufacturers to provide the Department of Health and Human Services with aggregate data related to product samples of drugs, devices, biologic products, and medical supplies given to hospitals, physicians, or other medical professionals during the previous calendar year, beginning in 2023.